Home Investors  >  Financials  >  Debt Securities

Debt Securities

Teva's senior notes and debentures and convertible debentures are issued by various special-purpose finance subsidiaries. All such debt is guaranteed by Teva Pharmaceutical Industries Ltd.

Quarterly Debt Factsheet

Senior Notes and Debentures

Issued
Currency
Annual Interest
(%)
Principal Amount Issued
(U.S. $ in MM)
Current Outstanding
Due
Prospectuses
January 2006 USD 6.150 1,000 783 January 2036
November 2011 USD 3.650 1,750 1,136 November 2021
December 2012 USD 2.950 1,300 855 December 2022
March 2015 Euro 1.250 1,480 1,457 March 2023
March 2015 Euro 1.875 789 786 March 2027
July 2016 USD 2.200 3,000 1,474 July 2021
July 2016 USD 2.800 3,000 2,295 July 2023
July 2016 USD 3.150 3,500 3,494 October 2026
July 2016 USD 4.100 2,000 1,985 October 2046
July 2016 CHF 0.500 357 368 July 2022
July 2016 CHF 1.000 357 368 July 2025
July 2016 Euro 0.375 1,947 1,136 July 2020
Fully repaid at maturity

July 2016 Euro 1.125 1,669 1,680 October 2024
July 2016 Euro 1.625 834 837 October 2028
March 2018 USD 6.000 1,250 1,250 April 2024
March 2018 USD 6.750 1,250 1,250 March 2028
March 2018 Euro 3.250 867 787 April 2022
March 2018 Euro 4.500 1,115 1,008 March 2025
November 2019 USD 7.125 1,000 1,000 January 2025
November 2019 Euro 6.0 1,120 1,124 January 2025

Convertible Senior Debentures

Issued Annual interest rate
(%)
Initial Principal amount
(U.S. $ in MM)
Principal amount at 3/31/2017 Year due Conversion price August 2018
(U.S. $)
No of Teva shares issuable upon full conversion at 3/31/2017
(in MM)
Earliest date of redemption at issuer's option / repurchase at holder's option
January 2006(1) 0.25 $575 $514 2026 $39.7841 See footnote 1 Issuer - on demand
Holders - on 2/1/2021

To view the prospectus supplement relating to the January 2006 debentures - click here
For conversion and other notices - click here

(1) These convertible senior debentures due 2026 include a "net share settlement" feature according to which the principal of the debentures will be paid in cash and in the case of conversion, only the residual conversion value above the principal will be paid in Teva shares.

Term Loans and Other Facilities

Source Year
of
Facility
Currency Annual
Interest Rate (%)
(%)
Principal Amount
Issued
(U.S. $ in MM)
Due Additional Information

Revolving Credit Facility A

2019 USD USD Libor +1.60 - N/A $1.15 b facility available for 3 years with two 1 year extensions
$1.065 b extended for additional year

Revolving Credit Facility B

2019 USD USD Libor +1.80 - N/A $1.15 b facility available for 5 years

On April 8th Teva has entered into a new $2.3 billion revolving credit facility agreement. To view the new agreement – click here